
Travere Therapeutics Reports First Quarter 2022 Financial Results
NewsSAN DIEGO, May 5, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its first quarter 2022 financial results and provided a corporate update.
Read the full press release >






Travere Therapeutics Announces Plan for Chief Financial Officer Transition
News






Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders 43rd Annual Meeting and the Genetic Metabolic Dieticians International Conference 2022
News






Travere Therapeutics Submits New Drug Application for Sparsentan for the Treatment of IgA Nephropathy
NewsSAN DIEGO, March 21, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) under Subpart H for accelerated approval of sparsentan for the treatment of IgA nephropathy (IgAN).
Read the full press release >

Coalition of healthcare organizations, experts push forward to improve equity in rare diseases
News






Travere Therapeutics Recognizes Rare Disease Day 2022 and Raises Awareness for People Living with Rare Disease
NewsSAN DIEGO, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) joins the National Organization for Rare Disorders (NORD), the European Organisation for Rare Diseases (EURORDIS), and the rare community worldwide in recognizing today as Rare Disease Day 2022.
Read the full press release >






Travere Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
NewsSAN DIEGO, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its fourth quarter and full year 2021 financial results and provided a corporate update.
Read the full press release >

Creating a Better Future for Families Affected by Rare Disease
News

For the CEO of Travere, running a rare disease company is personal
News
